menu
BCM - Baylor College of Medicine

Giving life to possible

Clinical Trials

Multi-Virus-Specific Cytotoxic T Lymphocytes (CTLs) Expressing CD19 Chimeric Receptors for Prophylaxis of Therapy of Relapse of Acute Lymphoblastic Leukemia Post Hemopoietic Stem Cell Transplantation (MULTIPRAT) H-23637 (H-23637)

H-23637: Multi-Virus-Specific Cytotoxic T Lymphocytes (CTLs) Expressing CD19 Chimeric Receptors for Prophylaxis of Therapy of Relapse of Acute Lymphoblastic Leukemia Post Hemopoietic Stem Cell Transplantation (MULTIPRAT): This study evaluates T cell specific for three viruses EBV, adenovirus and CMV that have been genetically engineered to recognize a protein called CD19 present on lymphoblastic leukemia cells in patients with early relapse of ALL post transplant.

For more information: http://www.clinicaltrials.gov/ct2/show/NCT00840853